- Home
- NXC vs SERA Comparison
NXC vs SERA Comparison
Compare NXC & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXC
- SERA
- Stock Information
- Founded
- NXC 1992
- SERA 2008
- Country
- NXC United States
- SERA United States
- Employees
- NXC N/A
- SERA N/A
- Industry
- NXC Investment Managers
- SERA Precision Instruments
- Sector
- NXC Finance
- SERA Health Care
- Exchange
- NXC Nasdaq
- SERA Nasdaq
- Market Cap
- NXC 83.5M
- SERA 90.6M
- IPO Year
- NXC N/A
- SERA 2021
- Fundamental
- Price
- NXC $12.95
- SERA $3.10
- Analyst Decision
- NXC
- SERA
- Analyst Count
- NXC 0
- SERA 0
- Target Price
- NXC N/A
- SERA N/A
- AVG Volume (30 Days)
- NXC 17.5K
- SERA 109.9K
- Earning Date
- NXC 01-01-0001
- SERA 11-05-2025
- Dividend Yield
- NXC 3.97%
- SERA N/A
- EPS Growth
- NXC N/A
- SERA N/A
- EPS
- NXC 0.19
- SERA N/A
- Revenue
- NXC N/A
- SERA $108,000.00
- Revenue This Year
- NXC N/A
- SERA $257.66
- Revenue Next Year
- NXC N/A
- SERA $435.22
- P/E Ratio
- NXC $70.47
- SERA N/A
- Revenue Growth
- NXC N/A
- SERA 0.94
- 52 Week Low
- NXC $11.86
- SERA $1.37
- 52 Week High
- NXC $13.70
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- NXC 56.45
- SERA 56.78
- Support Level
- NXC $12.88
- SERA $2.97
- Resistance Level
- NXC $13.05
- SERA $3.30
- Average True Range (ATR)
- NXC 0.10
- SERA 0.33
- MACD
- NXC 0.02
- SERA 0.00
- Stochastic Oscillator
- NXC 69.12
- SERA 62.65
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.